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Abstract
Introduction: The development of Philadelphia chromosome (Ph) negative acute leukemia/myelodysplastic
syndrome (MDS) in patients with Ph-positive chronic myeloid leukemia (CML) is very rare. The features of restrictive
usage and absence of partial T cell clones have been found in patients with CML. However, the T-cell clonal
evolution of Ph-negative malignancies during treatment for CML is still unknown.
Objective: To investigate the dynamic change of clonal proliferation of T cell receptor (TCR) Va and Vb subfamilies in
one CML patient who developed Ph-negative acute lymphoblastic leukemia (ALL) after interferon and imatinib therapy.
Methods: The peripheral blood mononuclear cells (PBMC) samples were collected at the 3 time points (diagnosis
of Ph-positive chronic phase (CP) CML, developing Ph-negative ALL and post inductive chemotherapy (CT) for
Ph-negative ALL, respectively). The CDR3 size of TCR Va and Vb repertoire were detected by RT-PCR. The PCR
products were further analyzed by genescan to identify T cell clonality.
Results: The CML patient who achieved complete cytogenetic remission (CCR) after 5 years of IFN-a therapy
suddenly developed Ph-negative ALL 6 months following switch to imatinib therapy. The expression pattern and
clonality of TCR Va/Vb T cells changed in different disease stages. The restrictive expression of Va/Vb subfamilies
could be found in all three stages, and partial subfamily of T cells showed clonal proliferation. Additionally, there
have been obvious differences in Va/Vb subfamily of T cells between the stages of Ph-positive CML-CP and
Ph-negative ALL. The Va10 and Vb3 T cells evolved from oligoclonality to polyclonality, the Vb13 T cells
changed from bioclonality to polyclonality, when Ph-negative ALL developed.
Conclusions: Restrictive usage and clonal proliferation of different Va/Vb subfamily T cells between the stages of
Ph-positive CP and Ph-negative ALL were detected in one patient. These changes may play a role in Ph- negative
leukemogenesis.
Introduction
Chronic myeloid leukemia (CML) is genetically charac-
terized by the presence of the reciprocal translocation t
(9; 22) (q34; q11), resulting in a BCR/ABL gene fusion
on the derivative chromosome 22 called the Philadelphia
chromosome (Ph). Blastic transformation (BT) remains a
dire outcome of CML patients with a poor prognosis.
Non-random additional chromosome abnormalities
accompanied by Philadelphia chromosome can be
detected in 60-80% of cases in BT [1]. Recently, how-
ever, the development of chromosomal abnormalities in
Ph-negative cells [2] and isolated instances of Ph-nega-
tive acute leukemia or high-risk MDS during treatment
for CML have been reported [2-10]. The clonal origin of
Ph-negative leukemic clone is still unknown,. It is possi-
ble that it may originate from a de novo leukemic stem
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such as interferon, imatinib or other agents.
T cell immunodeficiency was suggested to play an
important role in tumor patients by facilitating the
expansion of a malignant clone [11,12]. Clonally
expanded T-cells were identified in peripheral blood or
tumor infiltrating T-cells (TIL), which are thought to
play a pivotal role in the adaptive immune responses by
recognizing antigen- derived peptides bound to MHC
molecules. The clonality of T-cells could be identified
by analysis of CDR3 size of 24 TCR Vb genes using RT-
PCR and genescan, which is called “immunoscope”
[13,14]. Several studies on TCR Vb repertoire showed
that skewed expression of TCR Vb subfamilies is a com-
mon feature in leukemia patients [15-18]. Clonally
expanded T cells with restricted TCR Vb usage can
recognize tumor cells in patients with both solid tumors
and leukemia [16,19,20].
It has been reported that leukemia-associated antigen
can induce specific clonal expansion of host T-cells or
the allogeneic T-cells. These activated T-cells have
been shown to display potential cytotoxic activity
against primary leukemic cells. Thus, it may be useful
for eradication of minimal residual leukemic cells by
activating autologous or allogeneic cytotoxic cells. In
particular, specific CTLs may be a promising tool in
the treatment of myelogenous leukemia [16,17,21]. Our
previous study showed that clonal expansion of T-cells
could be induced by CML associated antigen [16].
However, it is unclear how the clonally expanded TCR
Vb T-cells in CML patients are related to the develop-
ment of Ph-negative acute leukemia. In the present
study, we have used reverse transcription polymerase
chain reaction (RT-PCR) and the genescan analysis to
assay for TCR Va and Vb gene utilization and clonal
expansion in a patient who developed Ph-negative
acute lymphoblastic leukemia while in CML complete
remission following interferon and imatinib mesylate
therapy.
Methods
Case history
A 10-year-old female presented to our hospital in Octo-
ber 2000 because of excessive tiredness, epistaxis and
weight loss. Examination revealed moderate hepatosple-
nomegaly, and a blood count showed hemoglobin 102
g/L, white cell count 179 × 10
9/L, blasts 1%, promyelo-
cytes 8%, myelocytes 10%, metamyelocytes 29%, eosino-
phils 1%, basophils 7%, bands 16%, polymorphs 26%,
lymphocytes 2% and platelets 917 × 10
9/L. Leukocyte
alkaline phosphatase was 11. Bone marrow examination
was consistent with chronic phase CML (CML-CP).
Cytogenetic studies showed 25/25 cells with 46, XX,
t(9;22), t(11;18), der(16), t(16;?) by R-banding technique.
Fluorescence in situ hybridization (FISH) and reverse
transcription polymerase chain reaction (RT-PCR) stu-
dies for BCR/ABL fusion gene were positive. She
received interferon-alpha (IFN-a) combined with hydro-
xyurea therapy. Hydroxyurea was discontinued three
weeks later, when white cell count decreased to 5.7 ×
10
9/L, and spleen and liver became non-palpable. Treat-
ment with IFN-a was commenced at a dose of 1.5 mil-
lion-units (MU)/day. BCR/ABL fusion gene remianed
positive (90%~100%) by FISH analysis, which was per-
formed once or twice per year from 2001 to 2005. In
May 2005, we boosted the dose of IFN-a from 1.5 to
3 MU/day. Unfortunately, the patient failed to tolerate
full-dose IFN-a due to leukopenia (1 × 10
9/L) compli-
cated with fever. We discontinued IFN-a therapy for
3 months. After this, the dose of IFN-a ranged from 1.5
to 3 MU per week according to white cell count. In Jan-
uary 2006, FISH analysis revealed that the patient
achieved complete cytogenetic remission (CCR). At this
time, IFN-a was stopped, and imatinib mesylate (IM,
400 mg/d) was given instead according to the patient’s
selection. BCR/ABL fusion gene was detected using
FISH analysis of marrow samples in March, May and
August 2006.
In October 2006, the patient was admitted to our
department again due to sudden onset of overall osteo-
dynia, especially both in lower extremities, sternum
and ribs. A blood count showed hemoglobin 102 g/L,
white cell count 5.72 × 10
9/L, myelocytes 1%, bands
14%, polymorphs 24%, monocytes 12%, eosinophils 1%,
lymphocytes 48% and platelets 75 × 10
9/L. Bone mar-
row smear revealed 95% blasts that expressed CD34,
HLA-DR and the lymphoid antigens CD19, CD20 and
CD10. The blasts were myeloperoxidase negative by
cytochemistry staining, and cytogenetic analysis
showed 25/25 cells with 46, XX. Repeat FISH analysis
of this sample confirmed 200/200 metaphase cells to
be Ph-negative. After receiving two courses of induc-
tion chemotherapy consisting of CMOP regimen
(cyclophosphamide, mitoxantone, vincristine and pre-
dnisone) and FLAG regimen (fludarabine, cytoarabine
and granulocyte-cloning stimulating factor), respec-
tively, the patient achieved complete remission (CR).
Unfortunately bone marrow aspirate performed four
weeks later showed relapse with 67% lymphoblasts.
The karyotype was still normal, and BCR/ABL fusion
gene was still negative by FISH. The patient was trea-
ted palliatively and died of pulmonary invasive fungi
infection in June 2007.
Samples
After the patient’s consent, the bone marrow and per-
ipheral blood samples were collected in three different
disease stages of Ph-positive CP-CML, Ph-negative ALL
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Ph-negative ALL, respectively.
Cytogenetic, FISH and RT-PCR analysis for BCR/ABL
detection
Karyotype analyses were performed by R-banding tech-
nique. FISH was performed using LSI·bcr/abl dual color
probe (Vysis) that identified BCR/ABL rearrangement
derived from t (9; 22) (q34; q11.2). Three primers of
RT-PCR analyses for BCR/ABL detection were listed in
Table 1, and PCR was performed as described by Kawa-
saki ES et al [22].
Peripheral blood mononuclear cells (PBMC) isolation,
RNA isolation and cDNA synthesis
PBMC were isolated by Ficoll-Hypaque gradient centri-
fugation. RNA was extracted from the PBMC samples
according to the manufacturer’s recommendations (Tri-
zol, Gibco, USA): The quality of RNA was analyzed in
0.8% agarose gel stained with ethidium bromide. Two
μg RNA was reversely transcribed into the first single-
strand cDNA with random hexamer primers, using
reverse transcriptase, Superscript II Kit (Gibco, USA).
The quality of cDNA was confirmed by RT-PCR for b2
microglubin gene amplification.
RT-PCR for TCR Va and TCR Vb subfamily amplification
29 sense TCR Va primers and a single TCR Ca reverse
primer, or 24 TCR Vb sense primers and a single TCR
Cb primer were used in unlabeled PCR for amplification
of the TCR Va and Vb subfamilies respectively [23].
Subsequently, a runoff PCR was performed with fluores-
cent primers labelled at 5’ end with the FAM fluoro-
phore (Ca-FAM or Cb-FAM) purchased from TIB
MOLBIOL GmbH, Berlin, Germany. PCR was per-
formed as described by Puisieux I et al and our previous
studies [16,23,24]. Aliquots of the cDNA (1 μl) were
amplified in 25 μl reactions with one of the 29 Va pri-
mers and a Ca primer or one of 24 Vb primers and a
Cb primer. The final reaction mixture contained 0.5 μM
sense primer and antisense primer, 0.1 mM dNTP, 1.5
mM MgCl2, 1×PCR buffer and 1.25 U Taq polymerase
(Promega, USA). The amplification was performed on a
DNA thermal cycler (BioMetra, Germany). After 3 min
denaturation at 94°C, 40 PCR cycles were performed,
each cycle consisting of 94°C for 1 min, 60°C for 1 min
and 72°C for 1 min, and a final 7 min elongation at 72°
C. Then, the products were stored at 4°C.
Genescan analysis for TCR Va and TCR Vb subfamily
clonality analysis
Aliquots of the unlabeled PCR products (2 μl) were sub-
jected to a cycle of runoff reaction with fluorophore-
labelled Ca-fam or Cb-fam primer respectively. The
labelled runoff PCR products (2 μl) were heat-denatured
at 94°C for 4 min with 9.5 μl formamide (Hi-Di Forma-
mide, ABI, USA) and 0.5 μl of Size Standards (GENES-
CAN™-500-LIZ™, Perkin Elmer, ABI), the samples were
then loaded on 3100 POP-4™ gel (Performance Opti-
mized Polymer-4, ABI, USA) and resolved by electro-
phoresis in 3100 DNA sequencer (ABI, Perkin Elmer)
for size and fluorescence intensity determination using
Genescan software [16,23,24].
Results
Genetic feature of the CML case
Clinical, cytogenetic and molecular features of different
disease stage in this patient were listed in Table 2. Cyto-
genetic studies showed 25/25 cells with 46, XX, t(9;22),
t(11;18), der(16), t(16;?) by R-banding technique at the
diagnosis of CP-CML in October 2000. FISH and RT-
PCR studies for BCR/ABL fusion gene were also posi-
tive. In October 2006, when the patient was diagnosed
to have ALL, she had normal karyotype and negative
FISH and RT-PCR studies for BCR/ABL (Figure 1).
TCR Va and TCR Vb repertoire in PB T-cells
In different disease stage, the expression pattern of Va
and Vb repertoires was different. Only 9, 13 and 4 TCR
Va subfamilies were detected in PBMCs from the disease
stage of CP-CML, ALL and post CT for ALL, respec-
tively. TCR Vb subfamilies 4, 18 and 7 were detected in
PBMCs from the disease stage of CP-CML, ALL and post
CT, respectively, whereas almost all Va and Vb subfami-
lies could be detected in healthy controls. When patient
developed ALL, 6 TCR Va and 14 TCR Vb subfamilies
were newly expressed, and 2 TCR Va (Va4a n dV a8)
subfamilies disappeared (Figure 2 and 3).
The clonality of TCR Va/Vb subfamily T-cells in different
disease stages
Polyclonality of T cells representing random rearrange-
ment of TCR genes were detected in most TCR Va/Vb
subfamily in PBMCs of the patient in different disease
stages. Clonal expansion of TCR Vb repertoire could be
found in some TCR Vb subfamilies, which displayed dif-
ferent pattern between CT and ALL. Vb13 or Vb9a n d
Vb17 were identified at the stage of CT and ALL respec-
tively. More oligoclonal TCR Vb T cells were detected
after CT for ALL in the patient (Figure 4 and 5).
Table 1 The sequence of primers used for detection of
BCR/ABL rearrangement
Primers Sequences
CML 1 (upstream) 5’-GGAGCTGCAGATGCTGACCAAC-3’
CML 2 (downstream) 5’-TCAGACCCTGAGGCTCAAAGTC-3’
CML 3 (upstream) 5’-CGCATGTTCCGGGACAAAAGC-3’
Wang et al. Journal of Hematology & Oncology 2010, 3:14
http://www.jhoonline.org/content/3/1/14
Page 3 of 7Discussion
Isolated instances of Ph-negative acute leukemia or
high-risk MDS have been observed in the course of
interferon-a [4,9] and imatinib therapy [2,3] or post
hematopoietic stem cell transplantation [5] for Ph-posi-
tive CML. In the present study, we reported a similar
case which developed Ph-negative acute lymphoblastic
leukemia following imatinib therapy for 6 months. It
was thought that the Ph-negative leukemic cells might
originate from a new malignant clone rather than pre-
vious Ph-positive clone [25]. The cause of this phenom-
enon remains unclear. In the present study, we
characterized the T-cell repertoires between the stages
of CML-CP and Ph- negative ALL. Our previous studies
showed that the clonally expanded T cells were asso-
ciated with a leukemia associated antigen [16]. The
newly generated malignant clone might express different
leukemia specific or associated antigen, which may
induce different response of TCR repertoire pattern. It
would be interesting to detect the evolution of T-cell
clonality in the patient at different disease status.
The features of restrictive usage and absence of par-
tial T cell clones could be found in patients with CML
[26], which indicate deficiency of cellular immunity in
CML patients. However, on the other hand, anti-CML
cytotoxic T-cell clones were also identified in patients
Table 2 Clinical, cytogenetic and molecular features of a patient with Ph-positive CML who developed Ph-negative
acute lymphoblastic leukemia after IFN-a and imatinib mesylate therapy
Date Disease stage
(Treatment)
Karyotype BCR/ABL
FISH RT-PCR
8/10/2000 CP 46, XX, t(9;22), t(11;18), der(16), t(16;?)[25] +ve(95%) +ve
3/3/2001 CP(IFN-a) ND +ve(95%) ND
21/12/2001 CP(IFN-a) 45, XX,-22,16q+ t(11;18)[1]/45, XX,-22,16q
+ t(9;22)t(11;18)[1]/46, XX,-22,16q+ t
(9;22)t(11;18)[18]/46, XX [5]
+ve(90%) ND
28/11/2002 CP(IFN-a) ND +ve(100%) ND
28/11/2003 CP(IFN-a) ND +ve(90%) ND
6/5/2004 CP(IFN-a) ND +ve(90%) ND
1/6/2005 CP(IFN-a) ND +ve(75%) ND
27/1/2006 CCR(IFN-a) ND -ve ND
8/3/2006 CCR (IM) ND -ve ND
11/5/2006 CCR (IM) ND -ve ND
9/8/2006 CCR (IM) ND -ve ND
8/10/2006 Ph-negative ALL 46, XX [25] -ve -ve
18/12/2006 Post CT for ALL 46, XX [25] -ve -ve
CP: chronic phase; ALL: acute lymphoblastic leukemia; CCR: complete cytogenetic response; Hu: hydroxyurea; IM: imatinib mesylate; CT: chemotherapy; +ve:
positive; -ve: negative; ND: not done.
Figure 1 The results of FISH and RT-PCR analyses of marrow samples aspirated during different disease stage in a patient with CML.
CP-CML, the sample from chronic phase (October 2000); ALL, from the disease stage of acute lymphoblastic leukemia (October 2006); Post-CT,
from post-induction chemotherapy for ALL (December 2006). + ve, BCR/ABL positive; - ve, BCR/ABL negative. (a) FISH analysis; (b) RT-PCR
analysis. Lane M, 100 bp molecular weight ladder; Lane K, K562 200 bp b3/a2 BCR/ABL positive control; Lane C: negative control; Lane CP-CML,
200 bp b3/a2 products; Lane ALL and Post-CT, BCR/ABL negative.
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Figure 3 Distributions and clonality of TCR Vb subfamilies in a CML patient with different disease stages (CP-CML, ALL and Post-CT).
Figure 4 The results of genescan of TCR Va subfamilies in a CML patient with different disease stages (CP-CML, ALL and Post-CT).
Figure 5 The results of genescan of TCR Vb subfamilies in a CML patient with different disease stages (CP-CML, ALL and Post-CT).
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cells from peripheral blood of CML patients or autolo-
gous T cells inducted by bcr-abl peptide and so on
[15]. In the present study, the TCR Va and Vb distri-
bution and T cell clonality were analyzed by RT-PCR-
genescan technique in a CML patient with different
disease stages. As expected, there are marked differ-
ence in the expressional number of TCR Va/Vb
between the disease stage of CP and that of Ph-nega-
tive ALL. Only 9 of all 29 Va and 4 of all 24 Vb subfa-
milies could be detected at the time of CP, while 13/29
Va and 18/24 Vb subfamilies could be found at the
time of Ph-negative ALL. Additionally, decreased num-
ber of TCR Va/Vb subfamilies was detected post che-
motherapy. The distinct distribution of clonal T cells
were also detected in different disease stage, the pat-
tern changes in the clonally expanded T cells between
the chronic phase CML and Ph-negative acute lympho-
blastic leukemia might represent the change of the
host cellular immune response. Obviously, the predo-
minant usage of TCR Vb subfamilies were TCR Vb3
and Vb13 in oligoclonal expanded T cells from CML-
CP, while the usage pattern changed to TCR Vb9a n d
Vb17, when acute lymphoblastic leukemia developed.
T h i sp h e n o m e n o nm a yb ec a u s e db yl e u k e m i ca n t i g e n
variation due to leukemia clonal change from a Ph-
positive clone to a Ph-negative clone. Although the
antigenic peptides leading to clonal T-cell selection in
CML are unknown, the change of TCR Vb clones
might provide the information for host immune
response. After two courses of chemotherapy for Ph-
negative ALL, the decrease of TCR subfamilies includ-
ing Va and Vb were possibly induced by chemother-
apy. There are two possible mechanisms to interpret
the occurrence of oligoclonal T cells, including immu-
nity response to novel leukemic antigen and immuno-
suppression by chemotherapy.
In the present study, oligoclonally- expanded T cells
seem unmarked, when the TCR Va repertoire analysis
was used. Oligoclonally- expanded T cells was found
only in Va10 subfamily in CML-CP, which changed to
polyclonally expanded T cells in ALL. It may indicate
that the polyclonally expanded pattern was a common
feature in TCR Va subfamily T cells. Thus, the TCR Vb
repertoire analysis was thought more sensitive for
detecting clonally expanded T cells in immune response,
at least, in the present CML case.
T oo u rk n o w l e d g e ,t h i si st h ef i r s ti n v e s t i g a t i o no f
T-cell clonal changes in Ph-negative ALL and Ph-posi-
tive CML in the same patient. More cases of secondary
Ph-negative leukemia/MDS are needed to better charac-
terize the clonal expansion and evolution of T-cell
repertoire.
Conclusions
Restrictive usage and clonal proliferation of different Va/
Vb subfamily T cells between the stages of Ph-positive CP
and Ph-negative ALL were detected in one patient. These
changes may play a role in Ph- negative leukemogenesis.
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